Evidence map›Paper›PMID 38202047›Full record

ReviewJournal of clinical medicine2023

Colorectal Cancer: Current Updates and Future Perspectives.

Rosa Marcellinaro, Domenico Spoletini, Michele Grieco, Pasquale Avella, Micaela Cappuccio, Raffaele Troiano, Giorgio Lisi, Giovanni M Garbarino, Massimo Carlini

Abstract readReview
In one paragraph

Review in Journal of clinical medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
71citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

71 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Article
  14. Review
  15. SYT8 as a potential prognostic biomarker and therapeutic predictor in colorectal cancer: insights from multi-cohort transcriptomic analyses.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026
    Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

11 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Rosa MarcellinaroDepartment of General Surgery, S. Eugenio Hospital, 00144 Rome, Italy.ORCID 0000-0002-7235-7477
Domenico SpoletiniDepartment of General Surgery, S. Eugenio Hospital, 00144 Rome, Italy.
Michele GriecoDepartment of General Surgery, S. Eugenio Hospital, 00144 Rome, Italy.
Pasquale AvellaDepartment of Clinical Medicine and Surgery, University of Naples "Federico II", 80138 Naples, Italy.ORCID 0000-0003-4910-5404
Micaela CappuccioDepartment of Clinical Medicine and Surgery, University of Naples "Federico II", 80138 Naples, Italy.ORCID 0000-0002-6079-4039
Raffaele TroianoDepartment of General Surgery, S. Eugenio Hospital, 00144 Rome, Italy.ORCID 0000-0002-1578-5694
Giorgio LisiDepartment of General Surgery, S. Eugenio Hospital, 00144 Rome, Italy.
Giovanni M GarbarinoDepartment of General Surgery, S. Eugenio Hospital, 00144 Rome, Italy.ORCID 0000-0003-3373-0328
Massimo CarliniDepartment of General Surgery, S. Eugenio Hospital, 00144 Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Colorectal cancer is a frequent neoplasm in western countries, mainly due to dietary and behavioral factors. Its incidence is growing in developing countries for the westernization of foods and lifestyles. An increased incidence rate is observed in patients under 45 years of age. In recent years, the mortality for CRC is decreased, but this trend is slowing. The mortality rate is reducing in those countries where prevention and treatments have been implemented. The survival is increased to over 65%. This trend reflects earlier detection of CRC through routine clinical examinations and screening, more accurate staging through advances in imaging, improvements in surgical techniques, and advances in chemotherapy and radiation. The most important predictor of survival is the stage at diagnosis. The screening programs are able to reduce incidence and mortality rates of CRC. The aim of this paper is to provide a comprehensive overview of incidence, mortality, and survival rate for CRC.

Indexed as

colorectal cancerincidencemortalityscreeningsurvival

Identifiers

PMID38202047
PMCPMC10780254

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.